Haute Capital Partners invests in the equity of unlisted Swiss and European companies, in deep tech, life sciences and health, and financial technology.
These are fields in which Switzerland has an established scientific and industrial base, in which development cycles are long, and in which access to growth capital remains narrow.
The company operates at different stages of maturity, from seed to established growth, in minority positions. It applies neither an exclusive sector focus nor a predefined ownership threshold. Each position rests on its own investment thesis.
Three principles govern the management of the portfolio: selection, support, time.
Selection. Identify companies whose growth trajectory is clear and whose value is not yet reflected in their valuation. The examination covers technological or industrial substance, the quality of the management team and the company's ability to finance its development.
Support. Go beyond the capital contribution: connections with co-investors, assistance with structuring, governance and market access. A minority position in a company that grows produces more value than control of a company that stagnates.
Time. Hold positions as lasting positions. An industrial thesis takes years to materialise. A shareholder who exits at the first step does not reap what he helped to build.
The investment guidelines are published on the investor page. The composition of the portfolio is on the portfolio page. New investments are announced in the newsroom.